Publications - Corcept Therapeutics

PUBLICATIONS

Scientific journal publications or scientific congress presentations may include information regarding investigational products or uses.

Adrenal tumors provide insight into the role of cortisol in NK cell activity

Greenstein et al. • 2021 • Endocr Relat Cancer . 2021 Jun 29;28(8):583-592. doi: 10.1530/ERC-21-0048.

Effect of Miricorilant, a Selective Glucocorticoid Receptor Modulator, on Olanzapine-Associated Weight Gain in Healthy Subjects: A Proof-of-Concept Study

Hunt et al • 2021 • Journal of Clinical Psychopharmacology: August 6, 2021

Suppression of Tumor Immune Activity in Adrenocortical Carcinoma with Excess Glucocorticoid

Greenstein et al. • 2020 • AACR Annual Meeting 2020

Impact of relacorilant, a selective glucocorticoid receptor antagonist, on the immunosuppressive effects of endogenous cortisol.

Greenstein et al. • 2020 • Citation: J Clin Oncol 38: 2020 (suppl; abstract #: 3091)

Reversal of Antipsychotic-Induced Weight Gain in Rats with Miricorilant, a Selective Glucocorticoid Receptor (GR) Modulator

Lee et al. • 2020 • 2020 Annual Meeting - American Psychiatric Association (APA)

The Liver Meeting 2021 (American Association for the Study of Liver Diseases)

Kowdley et al • 2021 •

Relacorilant With Nab-paclitaxel: Safety and Activity in Patients With Pancreatic Ductal Adenocarcinoma and Ovarian Cancer

Munster et al. • 2019 •

Selective Glucocorticoid Receptor Modulation Prevents and Reverses Nonalcoholic Fatty Liver Disease in Male Mice

Koorneef et al. • 2018 • Endocrinology. 2018, 159(12):3925–3936

Selective glucocorticoid receptor (type II) antagonist prevents and reverses olanzapine-induced weight gain.

Belanoff et al. • 2010 • Diabetes Obes Metab. 2010;12(6):545-7.

A mixed glucocorticoid/mineralocorticoid selective modulator with dominant antagonism in the male rat brain.

Atucha et al. • 2015 • Endocrinology. 2015;156(11):4105-4114.